Robert Okada
Cardiovascular Disease · Tulsa, OKNPI 1003816877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,700 and has fallen 77.6% since, to $382 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in OK, where the typical reported total is $2,806.
Across 192 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$439
- Johnson & Johnson$433
- Novartis$236
- Boston Scientific$207
- Abbott$202
- Boehringer Ingelheim$200
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,00999%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $439 |
| Johnson & Johnson | 24 | $433 |
| Novartis | 19 | $236 |
| Boston Scientific | 14 | $207 |
| Abbott | 10 | $202 |
| Boehringer Ingelheim | 15 | $200 |
| AstraZeneca | 11 | $159 |
| Regeneron Healthcare Solutions, Inc. | 7 | $126 |
| Pfizer | 9 | $119 |
| Amarin Pharma, Inc. | 6 | $114 |
| Kowa Pharmaceuticals America, Inc. | 8 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $105 |
| Biotronik Inc. | 6 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Arbor Pharmaceuticals, Inc. | 5 | $72 |
| Merck | 5 | $69 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| Lundbeck LLC | 3 | $52 |
| Bayer | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Biosense Webster, Inc. | 1 | $22 |
| Nuwellis, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Medtronic | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
How this compares
$3,045 in reported general payments places this provider in the 50th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.